Acarbose, a Reliable Therapeutic Principle;Acarbose, ein bewährtes Therapieprinzip

Medizinische Klinik

Volumn 98, Issue SUPPL. 1, 2003, Pages 2-6

  Laube, Heiner ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Acarbose; Metabolic syndrome; Postprandial hyperglycemia; Therapeutic benefit

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

BLOOD; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES CONTROL; DIABETIC DIET; DIET THERAPY; DOSE RESPONSE; DRUG COMBINATION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; METABOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; POSTPRANDIAL STATE; SIDE EFFECT;

ACARBOSE; BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD;

EID: 0142229517     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Liebl A, Neiß A, Spannheimer A, et al. Kosten des Typ 2 Diabetes in Deutschland Ergebnisse der CODE 2 Studie. Dtsch Med Wochenschr 2002;126:585-9.
2. The Cochrane Controlled Trial Register. Available from URL (http:/www.update-software.com), 2001.
3. Zick R. Diabetes mellitus: Acarbose: Leitfaden für die Praxis. Kirchheim: Mainz, 2001.
4. Lebowitz HE. Alpha glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132-45.
5. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes. Data from a 5 year surveillance study. Diabetes Res Clin Pract 2001;52:193-204.
6. Hasche H, Mertes G, Bruns C, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999;12:277-85.
7. Hoffmann J, Spengler M. The Essen I Study. Efficacy of a 24 week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994;17:561-6.
8. Coniff RF, Shapiro TB, Hoogwerf BJ, et al. A double blind placebo controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin requiring type 2 diabetes. Diabetes Care 1995;18:928-32.
9. Hillebrand I, Boehme K, Frank G, et al. The effects of alpha-glucosidase inhibitor BAY g 5421 (acarbose) on meal stimulated elevations of circulating glucose, insulin and triglyceride level in man. Res Exp Med (Berl) 1979;175:81-6.
10. Laube H, Linn T, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998;106:231-3.
11. Qualmann C, Nauck MA, Holst JJ, et al. Glucagon-like peptide-1 (GLP-1) (17-36 amide) secretion in response to luminal glucosidase inhibition (acarbose). Scand J Gastroenterol 1995;30:892-6.
12. Baron AD, Eckel RH, Schmeiser L, et al. The effect of short term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type 2 diabetics. Metabolism 1987;36:409-15.
13. Tulp OL, Abdollahi A, Stevens C, et al. The effects of intestinal glucosidase inhibitor acarbose on cholesterol genesis in corpulent rats. Comp Biochem Physiol [A] 1991;100:763-8.
14. Rosenthal J, Mauenberger H. Hypertension in type 2 diabetic patients - effects of endogenous insulin and antidiabetic therapies. Am J Hypertens 2000;13:81A.
15. Calle-Pasqual A, Garcia-Honduvilla J, Martin-Alvarez PJ, et al. Influence of a 16 veek monotherapy with acarbose on cardiovascular risk factors in obese subjects with non insulin dependent diabetes mellitus. A controlled double blind comparison study with placebo. Diabetes Metab 1996;22:201-2.
16. Bayraktar M, van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 1996;19:252-4.
17. Ceriello A, Taboga C, Tonutti L, et al. Post meal coagulation in diabetes mellitus: the effect of acarbose. Diabetologia 1996;39:469-73.
18. Chiasson JL Josse RG, Gomis R. Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance. The STOP NIDDM Trial. Diabetologia 2002;45:Suppl 2:A104.
19. Chiasson JL, Josse RG, Gonus R, et al. Acarbose can prevent progression of impaired glucose tolerance to type 2 diabetes mellitus: results of a randomised clinical trial, the STOP-NIDDM Trial. Lancet 2002;359:2072-7.
20. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with imprived glucose tolerance. The STOP-NIDDH Trial. JAMA 2003;290:486-94.